Efficacy of Apremilast in Patients with Psoriasis with Limited Skin Involvement, Including High-Impact Site Involvement: A Pooled Analysis of Six Trials - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Effectiveness of Apremilast in Individuals with Psoriasis Exhibiting Minimal Skin Involvement and High-Impact Area Affected: A Combined Analysis of Six Clinical Trials

  • By

  • Bruce Strober

  • Mark Lebwohl

  • Peter van de Kerkhof

  • Linda Stein Gold

  • Joseph F. Merola

  • Yukari Okubo

  • Paolo Gisondi

  • Zhenwei Zhou

  • Siddharth Chaudhari

  • Cynthia Deignan

  • Ulrich Mrowietz

  • October 2, 2026

Share

  • 1

    The study evaluated apremilast efficacy in patients with plaque psoriasis and limited skin involvement (3–10% BSA) across six clinical trials.

  • 2

    Apremilast demonstrated enhanced skin clearance and improved quality of life by week 16, with benefits sustained through week 32.

  • 3

    The analysis included patients with high-impact site involvement affecting the scalp, genital area, and/or nails.

  • 4

    A total of 1152 patients were included in the pooled analysis, with 671 receiving apremilast and 481 receiving placebo.

  • 5

    Apremilast is supported as a systemic treatment option for individuals with limited plaque psoriasis and high-impact site involvement.

Original Source(s)

Efficacy of Apremilast in Patients with Psoriasis with Limited Skin Involvement, Including High-Impact Site Involvement: A Pooled Analysis of Six Trials

  • by Bruce Strober, Mark Lebwohl, Peter van de Kerkhof, Linda Stein Gold, Joseph F. Merola, Yukari Okubo, Paolo Gisondi, Zhenwei Zhou, Siddharth Chaudhari, Cynthia Deignan, Ulrich Mrowietz

  • October 2, 2026

Related Content

Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial

Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks

Triglycerides Linked to Psoriasis Risk

Genetically predicted triglyceride levels were associated with higher odds of psoriasis, while genetically predicted total fatty acid levels were not, in a two-sample Mendelian randomization analysis.